Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07315945

Implementation of an Allergic Rhinitis Severity Questionnaire in ENT Consultations

Allergic rhinitis is a very common condition (affecting 1 in 5 people in Europe) and a costly one for society (direct and indirect costs). Symptoms vary depending on the time of year, and treatments are primarily symptomatic, with follow-up in ENT consultations. Scientific societies (EAACI, FDA, EMA) recommend using a universal tool (severity score) (the CSMS score, SCST in French) to monitor severity and follow-up, and to obtain consistent data that can be extrapolated to other scientific data (meta-analyses).

Therefore, investigators in the ENT department use this SCST score (as well as others such as the SNOT 22 score) to assess the severity of allergic rhinitis in our patients and its progression.

Tbe investigators wish to confirm the acceptability of this tool for patients, and the statistical value of its properties.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Allergic Rhinitis Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Nose Diseases Otorhinolaryngologic Diseases Respiratory Hypersensitivity Respiratory Tract Diseases Rhinitis Rhinitis, Allergic

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Service d'ORL et de Chirurgie Cervico-faciale - CHU de Strasbourg - France

Strasbourg, 67091, France

Location status: Recruiting

Location contact

Léa Fath, MD

CONTACT

[email protected]

Léa Fath, MD

PRINCIPAL_INVESTIGATOR

Maxime FIEUX, Statistician

SUB_INVESTIGATOR

Thomas DOURLHÈS, MD

PRINCIPAL_INVESTIGATOR

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adult (≥18 years)
  • Follow-up at the ENT department of Hautepierre University Hospital for allergic rhinitis

Exclusion criteria

  • Asymptomatic individuals not requiring follow-up consultations.

Treatment and study plan

Primary outcomes

  1. Self-Assessment Clinical Symptom Score (SCST)

    Time frame: Up to 6 months

    • Rating Scale

    Each symptom is rated by the patient according to its intensity:

    • 0: absent
    • 1: mild
    • 2: moderate
    • 3: severe
    • Calculating the Score
    • Add the scores for each symptom.
    • The total SCST score reflects the overall severity of the symptoms:
    • Low score → mild symptoms
    • High score → severe symptoms
    • Interpretation
    • Before treatment: establish a baseline.
    • After treatment: compare the scores to assess effectiveness.
    • A decrease in the score indicates clinical improvement.

Study contacts

Contact information is provided by the study sponsor or research team.

Léa FATH, MD

CONTACT

[email protected]

33 3 88 12 76 52

Sponsors and collaborators

Lead sponsor

University Hospital, Strasbourg, France

Other

Registry information

Acronym: QSRA-ORL

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Jan 5, 2026
Registry last updated
Jan 5, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.